Antengene today announced that it will present the latest clinical data of its CD73 oral small molecule inhibitor ATG-037 and oral dual mTORC1/2 inhibitor ATG-008 in Poster Presentations at the 2025 ASCO. Read more： https://t.co/cR1ueZaAOo

Antengene today announced it has entered into a global clinical collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combination of ATG-022. Read more:

Antengene today announced that it has released results from four preclinical studies in poster presentations at the 2025 American Association for Cancer Research Annual Meeting (AACR 2025). Read more: https://t.co/iEcWqllHCU

Antengene today announced that it will release the latest clinical data of the CD73 small molecule inhibitor ATG-037 and the mTORC1/2 small molecule inhibitor ATG-008 in Poster Presentations at the ASCO 2025. Read more: https://t.co/dXub9gWCB3

Antengene today announced that it will release results from four preclinical studies in poster presentations at the 2025 American Association for Cancer Research Annual Meeting (AACR 2025). Read more: https://t.co/t9Zd2B1mYs

Antengene today announced its full-year results for the period ending December 31, 2024, along with several significant milestones achieved in recent months. Read more:

Antengene today announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for three indications. Read more:

Antengene today announced that XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with R/R MM who have received at least two prior therapies, has been approved for reimbursement in Taiwan. More:

Antengene today announced that it presented the latest data from two clinical studies of selinexor in two posters at the 2024 American Society of Hematology Annual Meeting (ASH 2024). Read more: https://t.co/MLTscZGnnx

Antengene today announced that the new indication of XPOVIO® (selinexor) has been included into the 2024 China National Reimbursement Drug List (NRDL). Read more:

Antengene today announced that it will present the latest data from two clinical studies of selinexor in two Posters at the 2024 American Society of Hematology Annual Meeting (ASH 2024). Read more： https://t.co/qAcRgJTLYf

Antengene today announced that it will present results from three programs at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC 2024) to be held in Houston, the United States from November 6-10, 2024. Read more： https://t.co/7HZP9zM2qb

Antengene today announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a supplemental New Drug Application (sNDA) for XPOVIO® (selinexor). Read more:

Antengene today announced that the Thailand Food and Drug Administration has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for two indications. Read more:

Antengene today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The Company will share the latest advancements in R&D during a Fireside Chat. Read more： https://t.co/LfUb4Kl2JJ

Antengene Corporation ( https://t.co/0tZnZsAJ3S) today announced its interim results for the period ending June 30, 2024, along with several significant milestones achieved in recent months. Read more:

Antengene today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for two indications. Read more:

Antengene today announced that the China National Medical Products Administration (NMPA) has approved a new indication of XPOVIO® (selinexor) . Read more:

Antengene today announced that South Korea’s National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM). Read more:

Antengene today announced its participation in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. Read more: